Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.36

+2.0%

Nov 26 2:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bladerunner17 who wrote (138)	1/4/2018 7:26:52 PM
From: Miljenko Zuanic	of 294

Maybe I am mistaking, but seams to me that TTI-621 has small chances (except intratumoral delivery for localized cancer) to stand on its own. So, going forward, they have work to complete showing potential partner that there is significant opportunity in combination. Normally, potential partner need to be pre-deal involved in R&D efforts, to do considered as serious partner. By this, I do not see share to advance forward near term. I do not see rush to increase position. I do have "not so big" position, and am OK. For what is worth, my 2 cents.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next